Precision BioSciences (DTIL) Q3 2026 earnings review
Precision BioSciences advances two clinical trials, but share count rises
Precision BioSciences, a clinical-stage gene editing company, moved its Duchenne muscular dystrophy therapy into human testing while leaning on share sales to preserve cash. Chief executive Michael Amoroso confirmed the first Duchenne patient received treatment in August, and its hepatitis B program secured a late-breaking presentation slot for November 8. Operating loss was $20 million, yet cash dipped by only $4 million to $108 million as the share count grew.
| Total cash (including restricted) | $108.0M down $4.4M from last quarter |
|---|---|
| Operating loss | $20.4M $20.7M a year ago |
| Common shares outstanding | 27.9M +5.5% from last quarter |
| Cash runway outlook | Unchanged funded through 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because clinical progress on both lead drugs arrived alongside ongoing share dilution and stretched timelines. Treating the first Duchenne boy resolves the spring delay, and partnered trials in multiple sclerosis and lymphoma posted strong patient responses. On the other hand, Duchenne efficacy readouts now sit in 2027, administrative costs rose from a year ago, and keeping the 2028 runway required issuing 1.5 million new shares in three months.
The question now is whether the hepatitis B drug can eliminate viral DNA safely across larger patient groups so the trial can enter Phase 2. If the expanded cohorts show durable viral clearance, the therapy could attract partner funding; if dose selection drags on, current shareholders face steady dilution to fund the trials. The November 8 liver conference presentation and year-end Duchenne safety update will decide.
🐂 Bull Case
First Duchenne Patient Dosed After Delay
PBGENE-DMD is Precision BioSciences' experimental gene editing treatment for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease in boys. Chief executive Michael Amoroso said the team "commenced dosing of the first patient in the FUNCTION-DMD trial" in August at Arkansas Children's Hospital. The therapy cuts out a faulty section of DNA to "restore near full-length functional dystrophin", the muscle protein missing in patients.
Starting human dosing is a vital step because the company originally aimed to treat the first boy in the spring and missed that target. A second hospital, Washington University in St. Louis, is now recruiting patients aged two to seven. Still, one dosed patient only softens the execution delay rather than ending it, because the trial needs at least ten patients before meeting regulators.
What to watch: initial safety results targeted for the end of 2026. Clean safety across multiple boys would show the dual-nuclease delivery works in humans without triggering severe immune reactions.
Hepatitis B Trial Gains Late-Breaking Slot
PBGENE-HBV is the gene editor's wholly owned treatment designed to cure chronic hepatitis B by destroying the viral DNA reservoir inside liver cells. In October, the American Association for the Study of Liver Diseases selected the program for a late-breaking oral presentation on November 8, 2026. During the third quarter, the biotech kept dosing more patients to gather additional liver biopsy and blood data.
Earlier data in May showed the drug eliminated viral DNA in liver biopsies from two patients, so the upcoming presentation will test whether that result holds in a larger group. Research and development spending fell 4.5% from a year ago to $12.7 million as early lab work ended, even as clinical trial costs for hepatitis B grew.
What to watch: the November 8 presentation data on viral DNA elimination and liver safety across cohorts. Durable viral loss without liver toxicity would support moving into Phase 2.
Partnered Programs Post Encouraging Early Data
Precision licenses its older cell therapy and gene insertion drugs to outside partners in exchange for future milestone payments. Three partner programs shared clinical updates across August and October:
- Multiple sclerosis (TG Therapeutics): 89% of evaluable patients had stable or improved disability scores at day 90.
- Lymphoma (Imugene): overall response rates reached 81% in cohort 2 and 86% in cohort 3, with regulatory alignment for a pivotal trial.
- Metabolic disease (iECURE): low-dose treatment cut severe ammonia crises by 74%, with Phase 1/2 dosing completed.
The company recorded zero revenue this quarter because no partner crossed a payment trigger, but advancing trials bring those payouts closer. Precision remains eligible for up to $288.6 million in future milestones from TG Therapeutics alone.
What to watch: Imugene's start date for its pivotal lymphoma study. Starting that trial or advancing the multiple sclerosis study would trigger non-dilutive cash payments.
🐻 Bear Case
Runway Through 2028 Relies on Selling Shares
Precision ended September with $108.0 million in cash, cash equivalents and restricted cash. The drug developer repeated that "existing cash and cash equivalents, continued fiscal and operating discipline, and availability of Precision’s at-the-market facility will fund the Company’s cash runway through 2028". An at-the-market facility lets a company sell new shares directly into the public market.
The numbers show that ongoing share sales are doing the heavy lifting. Operating loss was $20.4 million in the third quarter, yet total cash dropped by only $4.4 million from June's $112.4 million. Meanwhile, common shares outstanding rose by 1.46 million, or 5.5% in a single quarter, to 27.89 million. By our math, funding nine quarters through 2028 on $81.7 million of unencumbered cash allows only $9.1 million of quarterly burn.
What to watch: fourth-quarter cash flow and share sales in the annual filing. Continued quarterly issuance above one million shares would confirm that the 2028 runway comes at the cost of steady dilution.
Key Clinical Readouts Keep Slipping Into 2027
Early in 2026, Precision planned to deliver initial safety and muscle biopsy efficacy data from multiple Duchenne patients by year-end, alongside selecting a Phase 2 dose for its hepatitis B drug in the first half. Both timelines have stretched out across recent updates.
For Duchenne, the company now has "initial safety data targeted for year-end 2026", while "efficacy data at distinct timepoints expected to follow in H1 and H2 2027". For hepatitis B, instead of starting Phase 2, the team is still "enrolling additional patients and expanding the 0.4 mg/kg and 0.65 mg/kg cohorts to support selection of the optimal dosing schedule for Phase 2 expansion". Slower trials mean the company burns cash for longer before proving its drugs work.
What to watch: whether the November hepatitis B update locks in a final Phase 2 dose schedule. Another delay in dose selection would push Phase 2 initiation deeper into 2027.
Administrative Costs Rose Again
In July 2025, Precision launched an efficiency program to cut annual operating costs and stretch its cash. That effort reduced general and administrative overhead — executive pay, legal and office costs — in each of the last four quarters compared to a year earlier.
In the third quarter, that cost reduction stalled. General and administrative expenses rose 4.8% from a year ago to $7.7 million, and climbed 13.5% from the second quarter's $6.8 million. Total operating expenses edged down just 1.2% from a year ago to $20.4 million, up from $19.2 million in the prior quarter. Because the company has no regular revenue, higher overhead directly increases the cash deficit that share sales must cover.
What to watch: fourth-quarter operating expenses in the full-year report. A second consecutive quarter above $20 million would show that cost savings have peaked as clinical trials expand.
Risks this quarter didn't answer
Two balance-sheet and cash-flow items from prior filings were not broken out in the third-quarter earnings release.
- At-the-market share sales proceeds: the release does not state how much cash came from issuing the 1.46 million new shares; the quarterly Form 10-Q cash flow statement will show the exact figure.
- Restricted cash and warrant terms: the $22.5 million loan collateral and $3.8 million executive severance escrow, plus the 8.6 million liability-classified warrants, await the Form 10-Q footnotes.
💲 Other KPIs
Reported net loss narrowed 65.2% from a year ago to $7.6 million, or $0.28 per share. However, that drop came from a $12.7 million non-cash accounting gain on warrant liabilities, which Precision noted "have no impact on operating cash runway". By our math, excluding warrant and fair-value marks leaves a clean net loss of $19.9 million, down 3.6% from a year ago.
Working capital — short-term assets minus short-term liabilities — fell 7.2% from $84.4 million in June and is down from $109.8 million at the end of 2025. Total liabilities dropped 14.9% in the quarter to $68.6 million because the non-cash gain on warrant liabilities reduced the recorded obligation on the balance sheet.
The average share count used to calculate loss per share rose 132.1% from 11.8 million a year ago, and increased from 25.9 million in the second quarter. The higher share count comes from last November's equity offering, partner share purchases, and ongoing share issuance.
🔮 Guidance
Unchanged. The biotech still expects its $108.0 million cash balance, cost discipline, and at-the-market share sales facility to fund operations through 2028. By our math, stretching $108.0 million across the nine quarters from September 2026 through December 2028 implies a maximum net cash drop of $12.0 million per quarter, or $9.1 million per quarter using unencumbered cash.
Unchanged for year-end safety, with new 2027 timing for efficacy. Following the first patient dose in August, the plan keeps initial safety data at the end of 2026 and sets efficacy readouts at distinct points in the first and second halves of 2027.
Unchanged. The company will present clinical data from the ELIMINATE-B trial at the liver disease conference on November 8, 2026, with abstract data releasing November 5, as it continues expanding cohorts to pick a Phase 2 dose.
❓ Key Questions
How much cash came from selling shares this quarter?
Total cash fell by only $4.4 million despite a $20.4 million operating loss, while common shares rose by 1.46 million. Knowing the exact proceeds from the at-the-market facility tells investors the true quarterly cash burn.
When will Precision lock in the Phase 2 hepatitis B dose?
The company originally aimed to pick the optimal dose in the first half of 2026, but is still expanding the 0.4 mg/kg and 0.65 mg/kg cohorts. A clear date for starting Phase 2 is needed to judge the path to approval.
How many boys have been dosed in the Duchenne study?
Precision dosed its first patient in August and opened a second hospital site in St. Louis. The number of boys treated before year-end determines how meaningful the initial safety readout will be.
Why did general and administrative expenses jump 13.5% from Q2?
Overhead costs rose to $7.7 million from $6.8 million last quarter, ending four straight quarters of year-over-year savings. Investors need to know if this increase is a one-time expense or a higher baseline.